1
|
Meyer C, Larghero P, Almeida Lopes B, Burmeister T, Gröger D, Sutton R, Venn NC, Cazzaniga G, Corral Abascal L, Tsaur G, Fechina L, Emerenciano M, Pombo-de-Oliveira MS, Lund-Aho T, Lundán T, Montonen M, Juvonen V, Zuna J, Trka J, Ballerini P, Lapillonne H, Van der Velden VHJ, Sonneveld E, Delabesse E, de Matos RRC, Silva MLM, Bomken S, Katsibardi K, Keernik M, Grardel N, Mason J, Price R, Kim J, Eckert C, Lo Nigro L, Bueno C, Menendez P, Zur Stadt U, Gameiro P, Sedék L, Szczepański T, Bidet A, Marcu V, Shichrur K, Izraeli S, Madsen HO, Schäfer BW, Kubetzko S, Kim R, Clappier E, Trautmann H, Brüggemann M, Archer P, Hancock J, Alten J, Möricke A, Stanulla M, Lentes J, Bergmann AK, Strehl S, Köhrer S, Nebral K, Dworzak MN, Haas OA, Arfeuille C, Caye-Eude A, Cavé H, Marschalek R. The KMT2A recombinome of acute leukemias in 2023. Leukemia 2023; 37:988-1005. [PMID: 37019990 PMCID: PMC10169636 DOI: 10.1038/s41375-023-01877-1] [Citation(s) in RCA: 31] [Impact Index Per Article: 31.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2023] [Revised: 03/09/2023] [Accepted: 03/15/2023] [Indexed: 04/07/2023]
Abstract
Chromosomal rearrangements of the human KMT2A/MLL gene are associated with de novo as well as therapy-induced infant, pediatric, and adult acute leukemias. Here, we present the data obtained from 3401 acute leukemia patients that have been analyzed between 2003 and 2022. Genomic breakpoints within the KMT2A gene and the involved translocation partner genes (TPGs) and KMT2A-partial tandem duplications (PTDs) were determined. Including the published data from the literature, a total of 107 in-frame KMT2A gene fusions have been identified so far. Further 16 rearrangements were out-of-frame fusions, 18 patients had no partner gene fused to 5'-KMT2A, two patients had a 5'-KMT2A deletion, and one ETV6::RUNX1 patient had an KMT2A insertion at the breakpoint. The seven most frequent TPGs and PTDs account for more than 90% of all recombinations of the KMT2A, 37 occur recurrently and 63 were identified so far only once. This study provides a comprehensive analysis of the KMT2A recombinome in acute leukemia patients. Besides the scientific gain of information, genomic breakpoint sequences of these patients were used to monitor minimal residual disease (MRD). Thus, this work may be directly translated from the bench to the bedside of patients and meet the clinical needs to improve patient survival.
Collapse
Affiliation(s)
- C Meyer
- DCAL/Institute of Pharm. Biology, Goethe-University, Frankfurt/Main, Germany
| | - P Larghero
- DCAL/Institute of Pharm. Biology, Goethe-University, Frankfurt/Main, Germany
| | - B Almeida Lopes
- DCAL/Institute of Pharm. Biology, Goethe-University, Frankfurt/Main, Germany
- Instituto Nacional de Câncer (INCA), Rio de Janeiro, RJ, Brazil
| | - T Burmeister
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Dept. of Hematology, Oncology and Tumor Immunology, Berlin, Germany
| | - D Gröger
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Dept. of Hematology, Oncology and Tumor Immunology, Berlin, Germany
| | - R Sutton
- Molecular Diagnostics, Children's Cancer Institute, Lowy Cancer Research Centre, UNSW, Sydney, NSW, Australia
| | - N C Venn
- Molecular Diagnostics, Children's Cancer Institute, Lowy Cancer Research Centre, UNSW, Sydney, NSW, Australia
| | - G Cazzaniga
- Tettamanti Research Center, Pediatrics, University of Milano-Bicocca/Fondazione Tettamanti, Monza, Italy
| | - L Corral Abascal
- Tettamanti Research Center, Pediatrics, University of Milano-Bicocca/Fondazione Tettamanti, Monza, Italy
| | - G Tsaur
- Regional Children's Hospital, Ekaterinburg, Russian Federation; Research Institute of Medical Cell Technologies, Ekaterinburg, Russian Federation
| | - L Fechina
- Regional Children's Hospital, Ekaterinburg, Russian Federation; Research Institute of Medical Cell Technologies, Ekaterinburg, Russian Federation
| | - M Emerenciano
- Instituto Nacional de Câncer (INCA), Rio de Janeiro, RJ, Brazil
| | | | - T Lund-Aho
- Laboratory of Clinical Genetics, Fimlab Laboratories, Tampere, Finland
| | - T Lundán
- Department of Clinical Chemistry and Laboratory Division, University of Turku and Turku University Hospital, Turku, Finland
| | - M Montonen
- Department of Clinical Chemistry and Laboratory Division, University of Turku and Turku University Hospital, Turku, Finland
| | - V Juvonen
- Department of Clinical Chemistry and Laboratory Division, University of Turku and Turku University Hospital, Turku, Finland
| | - J Zuna
- CLIP, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
| | - J Trka
- CLIP, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
| | - P Ballerini
- Biological Hematology, AP-HP A. Trousseau, Pierre et Marie Curie University, Paris, France
| | - H Lapillonne
- Biological Hematology, AP-HP A. Trousseau, Pierre et Marie Curie University, Paris, France
| | - V H J Van der Velden
- Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
| | - E Sonneveld
- Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
| | - E Delabesse
- Institut Universitaire du Cancer de Toulouse, Toulouse Cedex 9, France
| | - R R C de Matos
- Cytogenetics Department, Bone Marrow Transplantation Unit, National Cancer Institute (INCA), Rio de Janeiro, Brazil
| | - M L M Silva
- Cytogenetics Department, Bone Marrow Transplantation Unit, National Cancer Institute (INCA), Rio de Janeiro, Brazil
| | - S Bomken
- Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom
| | - K Katsibardi
- Division of Pediatric Hematology-Oncology, First Department of Pediatrics, National and Kapodistrian University of Athens, "Aghia Sophia" Children's Hospital, Athens, Greece
| | - M Keernik
- Genetics and Personalized Medicine Clinic, Tartu University Hospital, Tartu, Estonia
| | - N Grardel
- Department of Hematology, CHU Lille, France
| | - J Mason
- Northern Institute for Cancer Research, Newcastle University and the Great North Children's West Midlands Regional Genetics Laboratory, Birmingham Women's and Children's NHS Foundation Trust, Mindelsohn Way, Birmingham, United Kingdom
| | - R Price
- Northern Institute for Cancer Research, Newcastle University and the Great North Children's West Midlands Regional Genetics Laboratory, Birmingham Women's and Children's NHS Foundation Trust, Mindelsohn Way, Birmingham, United Kingdom
| | - J Kim
- DCAL/Institute of Pharm. Biology, Goethe-University, Frankfurt/Main, Germany
- Department of Laboratory Medicine, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Korea
| | - C Eckert
- Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Pediatric Oncology/Hematology, Berlin, Germany
| | - L Lo Nigro
- Centro di Riferimento Regionale di Ematologia ed Oncologia Pediatrica, Azienda Policlinico "G. Rodolico", Catania, Italy
| | - C Bueno
- Josep Carreras Leukemia Research Institute. Barcelona, Spanish Network for Advanced Therapies (RICORS-TERAV, ISCIII); Spanish Collaborative Cancer Network (CIBERONC. ISCIII); University of Barcelona, Barcelona, Spain
- Josep Carreras Leukemia Research Institute. Barcelona, Spanish Network for Advanced Therapies (RICORS-TERAV, ISCIII); Spanish Collaborative Cancer Network (CIBERONC. ISCIII); Department of Biomedicine. University of Barcelona; and Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
| | - P Menendez
- Centro di Riferimento Regionale di Ematologia ed Oncologia Pediatrica, Azienda Policlinico "G. Rodolico", Catania, Italy
| | - U Zur Stadt
- Pediatric Hematology and Oncology and CoALL Study Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - P Gameiro
- Instituto Português de Oncologia, Departament of Hematology, Lisbon, Portugal
| | - L Sedék
- Department of Pediatric Hematology and Oncology, Medical University of Silesia, Zabrze, Poland
| | - T Szczepański
- Department of Pediatric Hematology and Oncology, Medical University of Silesia, Zabrze, Poland
| | - A Bidet
- Laboratoire d'Hématologie Biologique, CHU Bordeaux, Bordeaux, France
| | - V Marcu
- Hematology Laboratory, Sheba Medical Center, Tel-Hashomer, Israel
| | - K Shichrur
- Molecular Oncology Laboratory, Schneider Children's Medical Center of Israel, Petah Tikva, Israel
| | - S Izraeli
- Pediatric Hematology-Oncology, Schneider Children's Medical Center, Petah Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - H O Madsen
- Department of Clinical Immunology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
| | - B W Schäfer
- Division of Oncology and Children's Research Centre, University Children's Hospital Zurich, Zurich, Switzerland
| | - S Kubetzko
- Division of Oncology and Children's Research Centre, University Children's Hospital Zurich, Zurich, Switzerland
| | - R Kim
- Hematology Laboratory, Saint Louis Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
- Université Paris Cité, INSERM/CNRS U944/UMR7212, Institut de recherche Saint-Louis, Paris, France
| | - E Clappier
- Hematology Laboratory, Saint Louis Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France
- Université Paris Cité, INSERM/CNRS U944/UMR7212, Institut de recherche Saint-Louis, Paris, France
| | - H Trautmann
- Laboratory for Specialized Hematological Diagnostics, Medical Department II, University Hospital Schleswig-Holstein, Kiel, Germany
| | - M Brüggemann
- Laboratory for Specialized Hematological Diagnostics, Medical Department II, University Hospital Schleswig-Holstein, Kiel, Germany
| | - P Archer
- Bristol Genetics Laboratory, North Bristol NHS Trust, Bristol, United Kingdom
| | - J Hancock
- Bristol Genetics Laboratory, North Bristol NHS Trust, Bristol, United Kingdom
| | - J Alten
- Department of Pediatrics, University Hospital Schleswig-Holstein, Kiel, Germany
| | - A Möricke
- Department of Pediatrics, University Hospital Schleswig-Holstein, Kiel, Germany
| | - M Stanulla
- Department of Pediatrics, MHH, Hanover, Germany
| | - J Lentes
- Institute of Human Genetics, Medical School Hannover, Hannover, Germany
| | - A K Bergmann
- Institute of Human Genetics, Medical School Hannover, Hannover, Germany
| | - S Strehl
- St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria
| | - S Köhrer
- St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria
- Labdia Labordiagnostik, Vienna, Austria
| | - K Nebral
- St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria
- Labdia Labordiagnostik, Vienna, Austria
| | - M N Dworzak
- St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria
- Labdia Labordiagnostik, Vienna, Austria
- St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria
| | - O A Haas
- St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria
- Labdia Labordiagnostik, Vienna, Austria
- St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria
| | - C Arfeuille
- Genetics Department, AP-HP, Hopital Robert Debré, Paris, France
| | - A Caye-Eude
- Genetics Department, AP-HP, Hopital Robert Debré, Paris, France
- Université Paris Cité, Inserm U1131, Institut de recherche Saint-Louis, Paris, France
| | - H Cavé
- Genetics Department, AP-HP, Hopital Robert Debré, Paris, France
- Université Paris Cité, Inserm U1131, Institut de recherche Saint-Louis, Paris, France
| | - R Marschalek
- DCAL/Institute of Pharm. Biology, Goethe-University, Frankfurt/Main, Germany.
| |
Collapse
|
2
|
Albarmawi H, Ng C, Price R, Shah A, Ogale S, Oxnard G, Lofgren K. PP01.36 Blood-Based Biomarker Testing in Advanced Non-Small Cell Lung Cancer: Adoption, Biomarker Assessment, and Therapy Selection. J Thorac Oncol 2023. [DOI: 10.1016/j.jtho.2022.09.062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
|
3
|
Moore JS, Robertson LJ, Price R, Curry G, Farnan J, Black A, Nesbit MA, McLaughlin JA, Moore T. Evaluation of the performance of a lateral flow device for quantitative detection of anti-SARS-CoV-2 IgG. Clin Immunol Commun 2022; 2:130-135. [PMID: 38013966 PMCID: PMC9472806 DOI: 10.1016/j.clicom.2022.09.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/02/2022] [Revised: 09/13/2022] [Accepted: 09/13/2022] [Indexed: 11/19/2022]
Abstract
INTRODUCTION The AbC-19™ lateral flow immunoassay (LFIA) performance was evaluated on plasma samples from a SARS-CoV-2 vaccination cohort, WHO international standards for anti-SARS-CoV-2 IgG (human), individuals ≥2 weeks from infection of RT-PCR confirmed SARS-CoV-2 genetic variants, as well as microorganism serology. METHODS Pre-vaccination to three weeks post-booster samples were collected from a cohort of 111 patients (including clinically extremely vulnerable patients) from Northern Ireland. All patients received Oxford-AstraZeneca COVID-19 vaccination for the first and second dose, and Pfizer-BioNTech for the third (first booster). WHO international standards, 15 samples from 2 variants of concern (Delta and Omicron) and cross-reactivity with plasma samples from other microorganism infections were also assessed on AbC-19™. RESULTS All 80 (100%) participants sampled post-booster had high positive IgG responses, compared to 38/95 (40%) participants at 6 months post-first vaccination. WHO standard results correlated with information from corresponding biological data sheets, and antibodies to all genetic variants were detected by LFIA. No cross-reactivity was found with exception of one (of five) Dengue virus samples. CONCLUSION These findings suggest BNT162b2 booster vaccination enhanced humoral immunity to SARS-CoV-2 from pre-booster levels, and that this antibody response was detectable by the LFIA. In combination with cross-reactivity, standards and genetic variant results would suggest LFIA may be a cost-effective measure to assess SARS-CoV-2 antibody status.
Collapse
Affiliation(s)
- J S Moore
- Biomedical Sciences Research Institute, Ulster University, Northern Ireland, United Kingdom
- Integrated Diagnostics Laboratory, Ulster University, 3-5a Frederick St, Belfast, Northern Ireland, United Kingdom
| | - L J Robertson
- Biomedical Sciences Research Institute, Ulster University, Northern Ireland, United Kingdom
- Integrated Diagnostics Laboratory, Ulster University, 3-5a Frederick St, Belfast, Northern Ireland, United Kingdom
| | - R Price
- Biomedical Sciences Research Institute, Ulster University, Northern Ireland, United Kingdom
| | - G Curry
- Biomedical Sciences Research Institute, Ulster University, Northern Ireland, United Kingdom
- Integrated Diagnostics Laboratory, Ulster University, 3-5a Frederick St, Belfast, Northern Ireland, United Kingdom
| | - J Farnan
- The Group Surgery, 257 North Queen Street, Belfast, Northern Ireland, United Kingdom
| | - A Black
- The Group Surgery, 257 North Queen Street, Belfast, Northern Ireland, United Kingdom
| | - M A Nesbit
- Biomedical Sciences Research Institute, Ulster University, Northern Ireland, United Kingdom
- Integrated Diagnostics Laboratory, Ulster University, 3-5a Frederick St, Belfast, Northern Ireland, United Kingdom
| | - J A McLaughlin
- Integrated Diagnostics Laboratory, Ulster University, 3-5a Frederick St, Belfast, Northern Ireland, United Kingdom
- Nanotechnology and Integrated Bioengineering Centre, Ulster University, Northern Ireland, United Kingdom
| | - T Moore
- Biomedical Sciences Research Institute, Ulster University, Northern Ireland, United Kingdom
- Integrated Diagnostics Laboratory, Ulster University, 3-5a Frederick St, Belfast, Northern Ireland, United Kingdom
| |
Collapse
|
4
|
Pollard S, Offenberger J, Lee F, Liu M, Alfonso-Cristancho R, Price R, Howarth P. THE SUSTAINED OCS-SPARING EFFECT OF MEPOLIZUMAB: RESULTS FROM THE REAL-WORLD REALITI-A STUDY AT 2 YEARS. Ann Allergy Asthma Immunol 2022. [DOI: 10.1016/j.anai.2022.08.625] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
5
|
Tickle JA, Sen J, Adams C, Furness DN, Price R, Kandula V, Tzerakis N, Chari DM. A benchtop brain injury model using resected donor tissue from patients with Chiari malformation. Neural Regen Res 2022; 18:1057-1061. [PMID: 36254993 PMCID: PMC9827764 DOI: 10.4103/1673-5374.355761] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
The use of live animal models for testing new therapies for brain and spinal cord repair is a controversial area. Live animal models have associated ethical issues and scientific concerns regarding the predictability of human responses. Alternative models that replicate the 3D architecture of the central nervous system have prompted the development of organotypic neural injury models. However, the lack of reliable means to access normal human neural tissue has driven reliance on pathological or post-mortem tissue which limits their biological utility. We have established a protocol to use donor cerebellar tonsillar tissue surgically resected from patients with Chiari malformation (cerebellar herniation towards the foramen magnum, with ectopic rather than diseased tissue) to develop an in vitro organotypic model of traumatic brain injury. Viable tissue was maintained for approximately 2 weeks with all the major neural cell types detected. Traumatic injuries could be introduced into the slices with some cardinal features of post-injury pathology evident. Biomaterial placement was also feasible within the in vitro lesions. Accordingly, this 'proof-of-concept' study demonstrates that the model offers potential as an alternative to the use of animal tissue for preclinical testing in neural tissue engineering. To our knowledge, this is the first demonstration that donor tissue from patients with Chiari malformation can be used to develop a benchtop model of traumatic brain injury. However, significant challenges in relation to the clinical availability of tissue were encountered, and we discuss logistical issues that must be considered for model scale-up.
Collapse
Affiliation(s)
- Jacqueline A. Tickle
- Aston Pharmacy School, College of Health and Life Sciences, Aston University, Birmingham, UK
| | - Jon Sen
- School of Medicine, Faculty of Medicine and Health Sciences, Keele University, Staffordshire, UK
| | | | | | - Rupert Price
- Department of Neurosurgery, Royal Stoke University Hospital, Stoke-on-Trent, UK
| | - Viswapathi Kandula
- Department of Neurosurgery, Royal Stoke University Hospital, Stoke-on-Trent, UK
| | - Nikolaos Tzerakis
- Department of Neurosurgery, Royal Stoke University Hospital, Stoke-on-Trent, UK
| | - Divya M. Chari
- School of Medicine, Faculty of Medicine and Health Sciences, Keele University, Staffordshire, UK,Correspondence to: Divya M. Chari, .
| |
Collapse
|
6
|
Friedman C, Swanton C, Spigel D, Bose R, Burris H, Yu W, Wang Y, Malato J, Price R, Darbonne W, Szado T, Schulze K, Sweeney C, Hainsworth J, Meric-Bernstam F, Kurzrock R. 66O MyPathway: A multiple target, multiple basket study of targeted treatments in tissue-agnostic cohorts of patients (pts) with advanced solid tumors. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
7
|
Cairns G, Burté F, Price R, O'Connor E, Toms M, Mishra R, Moosajee M, Pyle A, Sayer JA, Yu-Wai-Man P. A mutant wfs1 zebrafish model of Wolfram syndrome manifesting visual dysfunction and developmental delay. Sci Rep 2021; 11:20491. [PMID: 34650143 PMCID: PMC8516871 DOI: 10.1038/s41598-021-99781-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2020] [Accepted: 09/28/2021] [Indexed: 11/09/2022] Open
Abstract
Wolfram syndrome (WS) is an ultra-rare progressive neurodegenerative disorder defined by early-onset diabetes mellitus and optic atrophy. The majority of patients harbour recessive mutations in the WFS1 gene, which encodes for Wolframin, a transmembrane endoplasmic reticulum protein. There is limited availability of human ocular and brain tissues, and there are few animal models for WS that replicate the neuropathology and clinical phenotype seen in this disorder. We, therefore, characterised two wfs1 zebrafish knockout models harbouring nonsense wfs1a and wfs1b mutations. Both homozygous mutant wfs1a-/- and wfs1b-/- embryos showed significant morphological abnormalities in early development. The wfs1b-/- zebrafish exhibited a more pronounced neurodegenerative phenotype with delayed neuronal development, progressive loss of retinal ganglion cells and clear evidence of visual dysfunction on functional testing. At 12 months of age, wfs1b-/- zebrafish had a significantly lower RGC density per 100 μm2 (mean ± standard deviation; 19 ± 1.7) compared with wild-type (WT) zebrafish (25 ± 2.3, p < 0.001). The optokinetic response for wfs1b-/- zebrafish was significantly reduced at 8 and 16 rpm testing speeds at both 4 and 12 months of age compared with WT zebrafish. An upregulation of the unfolded protein response was observed in mutant zebrafish indicative of increased endoplasmic reticulum stress. Mutant wfs1b-/- zebrafish exhibit some of the key features seen in patients with WS, providing a versatile and cost-effective in vivo model that can be used to further investigate the underlying pathophysiology of WS and potential therapeutic interventions.
Collapse
Affiliation(s)
- G Cairns
- International Centre for Life, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK
- Interdisciplinary School of Health Science, Faculty of Health Sciences, University of Ottawa, Ottawa, Canada
| | - F Burté
- International Centre for Life, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK
| | - R Price
- International Centre for Life, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK
| | - E O'Connor
- Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, Canada
| | - M Toms
- UCL Institute of Ophthalmology, University College London, London, UK
| | - R Mishra
- John van Geest Centre for Brain Repair and MRC Mitochondrial Biology Unit, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
| | - M Moosajee
- UCL Institute of Ophthalmology, University College London, London, UK
- Moorfields Eye Hospital NHS Foundation Trust, London, UK
- Great Ormond Street Hospital for Children NHS Foundation, Trust, London, UK
| | - A Pyle
- The Wellcome Centre for Mitochondrial Research, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK
| | - J A Sayer
- International Centre for Life, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK
- Department of Renal Medicine, Freeman Hospital, The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
- National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne, UK
| | - P Yu-Wai-Man
- UCL Institute of Ophthalmology, University College London, London, UK.
- John van Geest Centre for Brain Repair and MRC Mitochondrial Biology Unit, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
- Moorfields Eye Hospital NHS Foundation Trust, London, UK.
- Cambridge Eye Unit, Addenbrooke's Hospital, Cambridge University Hospitals, Cambridge, UK.
| |
Collapse
|
8
|
Sundar S, Biggs S, Abraham M, Cook J, Watts N, Price R, Brack M, Brown N, Dixon L, Crowther O, Trenaman R, Quinn D, Hall W, Younie S. 1232 Trust-Wide Assessment of Delirium in Post-Operative Elective Surgery. Br J Surg 2021. [DOI: 10.1093/bjs/znab259.138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Abstract
Aim
Delirium is an acute change in cognition and associated with adverse patient outcomes. The incidence of post-operative delirium after elective non-cardiac surgery is unknown. We aimed to assess the incidence of post-operative delirium in this group and the effect on patient outcomes.
Method
Patients aged 65 and over who underwent elective non-cardiac surgery were identified on post-operative day three. Delirium screening was performed in real time using the validated 4-AT assessment tool. A retrospective review of the patients’ preoperative and perioperative record was conducted to collect demographics and identify risk factors for delirium. Outcome data was collected at 30 days. Patients with a positive delirium score (>4) underwent a more in-depth assessment and managing teams given a delirium management pack.
Results
75 (39 male) consecutive patients were screened over a period of 4 months. Median age 77 years and 18% had frailty assessed as “vulnerable”. The majority of patients (37.3%) underwent thoracic surgery, followed by hepatobiliary (17.3%), gynaecological (17.3%), colorectal (12%), maxillofacial (9.3%) and ENT (4%). 5.3% (4) of patients had a positive 4-AT screen. No patients had a formal delirium screen or diagnosis in the initial 48 hours. The median length of stay for patients with a positive screen was 8.5 days (IQR 7.5-12) compared to 8 days (IQR 5-13) for patients with a negative screen.
Conclusions
Reassuringly, rate of post-operative delirium following elective operations in our Trust are low (5%). Larger numbers of patients are required to assess the impact this has on patient outcomes and identify correlation with risk factors.
Collapse
Affiliation(s)
- S Sundar
- Bristol Royal Infirmary, Bristol, United Kingdom
| | - S Biggs
- Bristol Royal Infirmary, Bristol, United Kingdom
| | - M Abraham
- Bristol Royal Infirmary, Bristol, United Kingdom
| | - J Cook
- Bristol Royal Infirmary, Bristol, United Kingdom
| | - N Watts
- Bristol Royal Infirmary, Bristol, United Kingdom
| | - R Price
- Bristol Royal Infirmary, Bristol, United Kingdom
| | - M Brack
- Bristol Royal Infirmary, Bristol, United Kingdom
| | - N Brown
- Bristol Royal Infirmary, Bristol, United Kingdom
| | - L Dixon
- Bristol Royal Infirmary, Bristol, United Kingdom
| | - O Crowther
- Bristol Royal Infirmary, Bristol, United Kingdom
| | - R Trenaman
- Bristol Royal Infirmary, Bristol, United Kingdom
| | - D Quinn
- Bristol Royal Infirmary, Bristol, United Kingdom
| | - W Hall
- Bristol Royal Infirmary, Bristol, United Kingdom
| | - S Younie
- Bristol Royal Infirmary, Bristol, United Kingdom
| |
Collapse
|
9
|
Åhlén I, Vigouroux G, Destouni G, Pietroń J, Ghajarnia N, Anaya J, Blanco J, Borja S, Chalov S, Chun KP, Clerici N, Desormeaux A, Girard P, Gorelits O, Hansen A, Jaramillo F, Kalantari Z, Labbaci A, Licero-Villanueva L, Livsey J, Maneas G, Pisarello KLM, Pahani DM, Palomino-Ángel S, Price R, Ricaurte-Villota C, Fernanda Ricaurte L, Rivera-Monroy VH, Rodriguez A, Rodriguez E, Salgado J, Sannel B, Seifollahi-Aghmiuni S, Simard M, Sjöberg Y, Terskii P, Thorslund J, Zamora DA, Jarsjö J. Publisher Correction: Hydro-climatic changes of wetlandscapes across the world. Sci Rep 2021; 11:13400. [PMID: 34158573 PMCID: PMC8219735 DOI: 10.1038/s41598-021-92697-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Affiliation(s)
- I Åhlén
- Department of Physical Geography and Bolin Center for Climate Research, Stockholm University, 10691, Stockholm, Sweden.
| | - G Vigouroux
- Department of Physical Geography and Bolin Center for Climate Research, Stockholm University, 10691, Stockholm, Sweden
| | - G Destouni
- Department of Physical Geography and Bolin Center for Climate Research, Stockholm University, 10691, Stockholm, Sweden
| | - J Pietroń
- Department of Physical Geography and Bolin Center for Climate Research, Stockholm University, 10691, Stockholm, Sweden.,WSP Sverige AB, Ullevigatan 19, 411 40, Gothenburg, Sweden
| | - N Ghajarnia
- Department of Physical Geography and Bolin Center for Climate Research, Stockholm University, 10691, Stockholm, Sweden
| | - J Anaya
- Facultad de Ingeniería, Universidad de Medellín, Carrera 87 30-65, 050026, Medellín, Colombia
| | - J Blanco
- Facultad de Ciencias Exactas Y Naturales, Instituto de Biología, Universidad de Antioquia, Calle 70 No. 52-21, 050010, Medellín, Colombia
| | - S Borja
- Department of Physical Geography and Bolin Center for Climate Research, Stockholm University, 10691, Stockholm, Sweden
| | - S Chalov
- Faculty of Geography, Lomonosov Moscow State University, Moscow, Russia, 119991
| | - K P Chun
- Department of Geography, Hong Kong Baptist University, SAR, Hong Kong, China
| | - N Clerici
- Department of Biology, Faculty of Natural Sciences and Mathematics, Universidad del Rosario, 13409, Bogotá, DC, Colombia
| | - A Desormeaux
- School of Natural Resources and Environment, University of Florida, Gainesville, FL, 32603, USA
| | - P Girard
- Centro de Pesquisa do Pantanal and BioScience Institute, Federal University of Mato Grosso, Cuiabá, Mato Grosso, Brazil
| | - O Gorelits
- Zubov State Oceanographic Institute, Moscow, 119034, Russia
| | - A Hansen
- Department of Civil, Environmental and Architectural Engineering, University of Kansas, Lawrence, KS, 66045, USA
| | - F Jaramillo
- Department of Physical Geography and Bolin Center for Climate Research, Stockholm University, 10691, Stockholm, Sweden.,Baltic Sea Centre, 10691, Stockholm, Sweden
| | - Z Kalantari
- Department of Physical Geography and Bolin Center for Climate Research, Stockholm University, 10691, Stockholm, Sweden
| | - A Labbaci
- Department of Geology, Faculty of Sciences, Ibn Zohr University, Agadir, Morocco
| | - L Licero-Villanueva
- Institute of Botany and Landscape Ecology, University of Greifswald, 17489, Greifswald, Germany
| | - J Livsey
- Department of Physical Geography and Bolin Center for Climate Research, Stockholm University, 10691, Stockholm, Sweden
| | - G Maneas
- Department of Physical Geography and Bolin Center for Climate Research, Stockholm University, 10691, Stockholm, Sweden.,Navarino Environmental Observatory, 24 001, Messinia, Greece
| | - K L McCurley Pisarello
- Department of Soil and Water Sciences, University of Florida, Gainesville, FL, 32611, USA
| | - D Moshir Pahani
- Department of Physical Geography and Bolin Center for Climate Research, Stockholm University, 10691, Stockholm, Sweden
| | - S Palomino-Ángel
- Facultad de Ingeniería, Universidad de Medellín, Carrera 87 30-65, 050026, Medellín, Colombia.,Facultad de Ingeniería, Universidad de San Buenaventura, Carrera 56C N° 51-110, 050010, Medellín, Colombia
| | - R Price
- Department of Earth and Environment, Southeast Environmental Research Center, Florida International University, Miami, FL, 33199, USA
| | - C Ricaurte-Villota
- Instituto de investigaciones marinas y costeras de Colombia "José Benito Vives de Andreis"- INVEMAR, 470006, Santa Marta, Colombia
| | - L Fernanda Ricaurte
- Alexander von Humboldt Biological Resources Research Institute, Calle 28 A No. 15-09, 70803, Bogotá, DC, Colombia
| | - V H Rivera-Monroy
- Department of Oceanography and Coastal Sciences, College of the Coast and Environment, Louisiana State University, Baton Rouge, LA, 70803, USA
| | - A Rodriguez
- Instituto de investigaciones marinas y costeras de Colombia "José Benito Vives de Andreis"- INVEMAR, 470006, Santa Marta, Colombia
| | - E Rodriguez
- Civil and Agricultural Engineering Department, Universidad Nacional de Colombia, 11001, Bogotá, Colombia
| | - J Salgado
- Departamento de Ciencias Biológicas, Universidad de Los Andes, Cra. 1 No. 18A-12, 111711, Bogotá, Colombia.,Facultad de Ingeniería, Universidad Católica de Colombia, Av. Caracas No. 46-72, 111311, Bogotá, Colombia
| | - B Sannel
- Department of Physical Geography and Bolin Center for Climate Research, Stockholm University, 10691, Stockholm, Sweden
| | - S Seifollahi-Aghmiuni
- Department of Physical Geography and Bolin Center for Climate Research, Stockholm University, 10691, Stockholm, Sweden
| | - M Simard
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA, USA
| | - Y Sjöberg
- Department of Geosciences and Natural Resource Management, University of Copenhagen, Copenhagen, Denmark
| | - P Terskii
- Faculty of Geography, Lomonosov Moscow State University, Moscow, Russia, 119991
| | - J Thorslund
- Department of Physical Geography and Bolin Center for Climate Research, Stockholm University, 10691, Stockholm, Sweden.,Department of Physical Geography, Utrecht University, Utrecht, The Netherlands
| | - D A Zamora
- Civil and Agricultural Engineering Department, Universidad Nacional de Colombia, 11001, Bogotá, Colombia
| | - J Jarsjö
- Department of Physical Geography and Bolin Center for Climate Research, Stockholm University, 10691, Stockholm, Sweden
| |
Collapse
|
10
|
Cuthbert H, Pepper J, Price R. Spontaneous resolution of a Chiari malformation with syringomyelia. BMJ Case Rep 2021; 14:14/6/e241789. [PMID: 34155013 DOI: 10.1136/bcr-2021-241789] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
The Chiari I malformation (CM-I) is characterised by overcrowding of the posterior fossa and descent of the cerebellar tonsils and is associated with syringomyelia. With the increasing availability of magnetic resonance imaging, CM-I is placing a growing burden on neurosurgical services. However, its natural history remains poorly understood, and the timing and nature of surgical intervention is controversial. We present a case of a significant, symptomatic CM-I with associated syrinx which underwent complete spontaneous resolution over a 4-year period. Spontaneous regression of Chiari malformation and syringomyelia is exceedingly rare; a literature review reveals 15 other cases and only one case which underwent complete resolution. The present case and literature review suggest a more benign natural history of CM-I and support a more conservative approach to its management. Further studies are required to determine whether any factors can predict resolution for certain patient cohorts.
Collapse
Affiliation(s)
- Hadleigh Cuthbert
- Department of Neurosurgery, University Hospital of North Staffordshire NHS Trust, Stoke-on-Trent, UK
| | - Joshua Pepper
- Department of Neurosurgery, University Hospital of North Staffordshire NHS Trust, Stoke-on-Trent, UK
| | - Rupert Price
- Department of Neurosurgery, University Hospital of North Staffordshire NHS Trust, Stoke-on-Trent, UK
| |
Collapse
|
11
|
Kojic DD, El-Mowafy O, Price R, El-Badrawy W. The Ability of Dental Practitioners to Light-Cure Simulated Restorations. Oper Dent 2021; 46:160-172. [PMID: 34111286 DOI: 10.2341/19-147-c] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/29/2020] [Indexed: 11/23/2022]
Abstract
CLINICAL RELEVANCE Using a patient simulator, dental professionals were tested to determine their ability to light-polymerize simulated restorations in their dental practice. After receiving specific instructions and training using the simulator, their ability to deliver sufficient light to polymerize restorations was significantly and substantially improved. SUMMARY Objectives: To determine the ability of dental professionals to deliver a radiant exposure of at least six J/cm2 in 10 seconds to simulated restorations.Methods and Materials: The study initially examined 113 light-emitting-diode (LED) light polymerization units (LPUs) used in dental offices to determine if they could deliver at least 6 J/cm2 radiant exposure (RE) in 10s. This assessment was completed by using a laboratory-grade light measuring device (checkMARC, BlueLight Analytics, Halifax, NS, Canada). The participating dental professionals whose LPUs could deliver 6 J/cm2 then used their own LPU to light-cure simulated anterior and posterior restorations in the MARC Patient Simulator (BlueLight Analytics). They then received specific instructions and were retested using the same LPUs. Data were statistically analyzed with a series of one-way analysis of variance (ANOVA), two-way ANOVA, paired-samples t-tests, Fisher post hoc multiple comparison tests, and McNemar tests with a preset alpha of 0.05 (SPSS Inc).Results: Ten (8.8%) LPUs could not deliver the required RE to the checkMARC in 10s and were eliminated from the study. For the anterior restoration, most dental practitioners (87.3%) could deliver at least 6 J/cm2 before instructions. After receiving additional light-curing instructions, only two (1.9%) participants were unable to deliver 6 J/cm2 to the anterior location. At the posterior location, only 55.3% (57) participants could deliver at least 6 J/cm2 before the instructions. After receiving these instructions, an additional 32 participants delivered at least 6 J/cm2. Overall, after receiving instructions on how to use the LPU correctly, the participants improved the amount of RE they delivered to anterior and posterior restorations by 22.5% and 30%, respectively.Conclusion: This study revealed that at the baseline, 44.7% of participating dental professionals failed to deliver 6 J/cm2 in 10s to the posterior simulated restoration when using their own LPU.
Collapse
|
12
|
Åhlén I, Vigouroux G, Destouni G, Pietroń J, Ghajarnia N, Anaya J, Blanco J, Borja S, Chalov S, Chun KP, Clerici N, Desormeaux A, Girard P, Gorelits O, Hansen A, Jaramillo F, Kalantari Z, Labbaci A, Licero-Villanueva L, Livsey J, Maneas G, Pisarello KLM, Pahani DM, Palomino-Ángel S, Price R, Ricaurte-Villota C, Fernanda Ricaurte L, Rivera-Monroy VH, Rodriguez A, Rodriguez E, Salgado J, Sannel B, Seifollahi-Aghmiuni S, Simard M, Sjöberg Y, Terskii P, Thorslund J, Zamora DA, Jarsjö J. Hydro-climatic changes of wetlandscapes across the world. Sci Rep 2021; 11:2754. [PMID: 33531523 PMCID: PMC7854620 DOI: 10.1038/s41598-021-81137-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2020] [Accepted: 12/22/2020] [Indexed: 11/09/2022] Open
Abstract
Assessments of ecosystem service and function losses of wetlandscapes (i.e., wetlands and their hydrological catchments) suffer from knowledge gaps regarding impacts of ongoing hydro-climatic change. This study investigates hydro-climatic changes during 1976-2015 in 25 wetlandscapes distributed across the world's tropical, arid, temperate and cold climate zones. Results show that the wetlandscapes were subject to precipitation (P) and temperature (T) changes consistent with mean changes over the world's land area. However, arid and cold wetlandscapes experienced higher T increases than their respective climate zone. Also, average P decreased in arid and cold wetlandscapes, contrarily to P of arid and cold climate zones, suggesting that these wetlandscapes are located in regions of elevated climate pressures. For most wetlandscapes with available runoff (R) data, the decreases were larger in R than in P, which was attributed to aggravation of climate change impacts by enhanced evapotranspiration losses, e.g. caused by land-use changes.
Collapse
Affiliation(s)
- I Åhlén
- Department of Physical Geography and Bolin Center for Climate Research, Stockholm University, 10691, Stockholm, Sweden.
| | - G Vigouroux
- Department of Physical Geography and Bolin Center for Climate Research, Stockholm University, 10691, Stockholm, Sweden
| | - G Destouni
- Department of Physical Geography and Bolin Center for Climate Research, Stockholm University, 10691, Stockholm, Sweden
| | - J Pietroń
- Department of Physical Geography and Bolin Center for Climate Research, Stockholm University, 10691, Stockholm, Sweden.,WSP Sverige AB, Ullevigatan 19, 411 40, Gothenburg, Sweden
| | - N Ghajarnia
- Department of Physical Geography and Bolin Center for Climate Research, Stockholm University, 10691, Stockholm, Sweden
| | - J Anaya
- Facultad de Ingeniería, Universidad de Medellín, Carrera 87 30-65, 050026, Medellín, Colombia
| | - J Blanco
- Facultad de Ciencias Exactas y Naturales, Instituto de Biología, Universidad de Antioquia, Calle 70 No. 52-21, 050010, Medellín, Colombia
| | - S Borja
- Department of Physical Geography and Bolin Center for Climate Research, Stockholm University, 10691, Stockholm, Sweden
| | - S Chalov
- Faculty of Geography, Lomonosov Moscow State University, Moscow, Russia, 119991
| | - K P Chun
- Department of Geography, Hong Kong Baptist University, Hong Kong, SAR, China
| | - N Clerici
- Department of Biology, Faculty of Natural Sciences and Mathematics, Universidad del Rosario, 13409, Bogotá, DC, Colombia
| | - A Desormeaux
- School of Natural Resources and Environment, University of Florida, Gainesville, FL, 32603, USA
| | - P Girard
- Centro de Pesquisa do Pantanal and BioScience Institute, Federal University of Mato Grosso, Cuiabá, Mato Grosso, Brazil
| | - O Gorelits
- Zubov State Oceanographic Institute, Moscow, 119034, Russia
| | - A Hansen
- Department of Civil, Environmental and Architectural Engineering, University of Kansas, Lawrence, KS, 66045, USA
| | - F Jaramillo
- Department of Physical Geography and Bolin Center for Climate Research, Stockholm University, 10691, Stockholm, Sweden.,Baltic Sea Centre, 10691, Stockholm, Sweden
| | - Z Kalantari
- Department of Physical Geography and Bolin Center for Climate Research, Stockholm University, 10691, Stockholm, Sweden
| | - A Labbaci
- Department of Geology, Faculty of Sciences, Ibn Zohr University, Agadir, Morocco
| | - L Licero-Villanueva
- Institute of Botany and Landscape Ecology, University of Greifswald, 17489, Greifswald, Germany
| | - J Livsey
- Department of Physical Geography and Bolin Center for Climate Research, Stockholm University, 10691, Stockholm, Sweden
| | - G Maneas
- Department of Physical Geography and Bolin Center for Climate Research, Stockholm University, 10691, Stockholm, Sweden.,Navarino Environmental Observatory, 24 001, Messinia, Greece
| | - K L McCurley Pisarello
- Department of Soil and Water Sciences, University of Florida, Gainesville, FL, 32611, USA
| | - D Moshir Pahani
- Department of Physical Geography and Bolin Center for Climate Research, Stockholm University, 10691, Stockholm, Sweden
| | - S Palomino-Ángel
- Facultad de Ingeniería, Universidad de Medellín, Carrera 87 30-65, 050026, Medellín, Colombia.,Facultad de Ingeniería, Universidad de San Buenaventura, Carrera 56C N° 51-110, 050010, Medellín, Colombia
| | - R Price
- Department of Earth and Environment, Southeast Environmental Research Center, Florida International University, Miami, FL, 33199, USA
| | - C Ricaurte-Villota
- Instituto de investigaciones marinas y costeras de Colombia "José Benito Vives de Andreis"-INVEMAR, 470006, Santa Marta, Colombia
| | - L Fernanda Ricaurte
- Alexander von Humboldt Biological Resources Research Institute, Calle 28 A No. 15-09, Bogotá, DC, 70803, Colombia
| | - V H Rivera-Monroy
- Department of Oceanography and Coastal Sciences, College of the Coast and Environment, Louisiana State University, Baton Rouge, LA, 70803, USA
| | - A Rodriguez
- Instituto de investigaciones marinas y costeras de Colombia "José Benito Vives de Andreis"-INVEMAR, 470006, Santa Marta, Colombia
| | - E Rodriguez
- Civil and Agricultural Engineering Department, Universidad Nacional de Colombia, 11001, Bogotá, Colombia
| | - J Salgado
- Departamento de Ciencias Biológicas, Universidad de Los Andes, Cra. 1 No. 18A-12, 111711, Bogotá, Colombia.,Facultad de Ingeniería, Universidad Católica de Colombia, Av. Caracas No. 46-72, 111311, Bogotá, Colombia
| | - B Sannel
- Department of Physical Geography and Bolin Center for Climate Research, Stockholm University, 10691, Stockholm, Sweden
| | - S Seifollahi-Aghmiuni
- Department of Physical Geography and Bolin Center for Climate Research, Stockholm University, 10691, Stockholm, Sweden
| | - M Simard
- Jet Propulsion Laboratory, California Institute of Technology, Pasadena, CA, USA
| | - Y Sjöberg
- Department of Geosciences and Natural Resource Management, University of Copenhagen, Copenhagen, Denmark
| | - P Terskii
- Faculty of Geography, Lomonosov Moscow State University, Moscow, Russia, 119991
| | - J Thorslund
- Department of Physical Geography and Bolin Center for Climate Research, Stockholm University, 10691, Stockholm, Sweden.,Department of Physical Geography, Utrecht University, Utrecht, The Netherlands
| | - D A Zamora
- Civil and Agricultural Engineering Department, Universidad Nacional de Colombia, 11001, Bogotá, Colombia
| | - J Jarsjö
- Department of Physical Geography and Bolin Center for Climate Research, Stockholm University, 10691, Stockholm, Sweden
| |
Collapse
|
13
|
Liu M, Bel E, Kornmann O, Humbert M, Kaneko N, Martin N, Gilson M, Price R, Yancey S, Moore W. P211 CLINICIAN/PATIENT PERCEPTION: ASTHMA SEVERITY DECREASES AND RESPONSE INCREASES WITH CONTINUING VERSUS STOPPING LONG-TERM MEPOLIZUMAB (COMET). Ann Allergy Asthma Immunol 2020. [DOI: 10.1016/j.anai.2020.08.108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
14
|
Chapman K, Devouassoux G, Liu M, Chipps B, Munoz X, Bergna M, Gruber A, Price R, Smith S, Bourdin A. P205 SWITCH FROM OMALIZUMAB TO MEPOLIZUMAB IN SEVERE EOSINOPHILIC ASTHMA: EFFECT OF WEIGHT AND BMI. Ann Allergy Asthma Immunol 2020. [DOI: 10.1016/j.anai.2020.08.102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
15
|
Kunnel Jomon M, Pepper J, O'Connor N, Price R. Regression of a spinal schwannoma after Pomalidomide. Br J Neurosurg 2020:1-2. [PMID: 32188281 DOI: 10.1080/02688697.2020.1742292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
A 77-year old female with a history of neurofibromatosis type 2 (NF2) was diagnosed with a spinal schwannoma that was managed conservatively over a decade. During this time, follow up imaging revealed this lesion had been growing and the patient had become symptomatic from it necessitating surgical decompression. However, the patient had been diagnosed with multiple myeloma and underwent treatment with Pomalidomide chemotherapy which delayed surgery for the spinal schwannoma. Further imaging of the spine revealed significant regression in the size of the spinal schwannoma. This phenomenon has not previously been reported and this report aims to explore the implications of Pomalidomide in patients with NF2 related spinal schwannomas.
Collapse
Affiliation(s)
- Mathew Kunnel Jomon
- Neurosurgery Department, University Hospital of North Midlands, Stoke on Trent, UK
| | - Joshua Pepper
- Neurosurgery Department, University Hospital of North Midlands, Stoke on Trent, UK
| | - Nigel O'Connor
- Haematology Department, Royal Shrewsbury Hospital, Shrewsbury, UK
| | - Rupert Price
- Neurosurgery Department, University Hospital of North Midlands, Stoke on Trent, UK
| |
Collapse
|
16
|
Veltchev I, Price R, Chen X, Howell K, Meyer J, Ma CM. Application of a directional palladium-103 brachytherapy device on a curved surface. Med Phys 2019; 46:1905-1913. [PMID: 30734318 DOI: 10.1002/mp.13427] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2018] [Revised: 01/28/2019] [Accepted: 01/28/2019] [Indexed: 11/08/2022] Open
Abstract
PURPOSE The directional planar palladium-103 LDR device (CivaSheet TM ) may be used for intraoperative implantation at the interface between the tumor site and healthy tissue. Its dosimetric properties have been studied in the ideal case of application on a flat surface. The dosimetric impact of implanting this highly directional device on a curved surface that may be encountered in clinical treatments is analyzed. METHODS CivaSheet is designed as an array of directional palladium-103 sources (CivaDots). From the postoperative computed tomography (CT) scans of three patients, the shape of each implanted CivaSheet was reconstructed. In order to obtain a realistic estimate of the distribution of curvatures, the mean radius of curvature at the location of each CivaDot was calculated. A Monte Carlo simulation (FLUKA) of a single CivaDot was designed, based upon published geometry and material specifications. Both the radial dose function analog and the two-dimensional anisotropy function analog for the CivaDot were validated in comparison with film measurements and benchmarked to published Monte Carlo data. A value for the dose-rate constant Λ = 0.587(19) cGy/h/U for a CivaDot source in water was calculated as well. Knowledge of the dose distribution in the vicinity of each source allowed the dose at any point around CivaSheets of different curvatures and orientations to be calculated. RESULTS The local radius of curvature was found to be primarily between 2 and 8 cm in all three patient implants. On the unshielded side of an inward-facing curved CivaSheet implant of radius 2 cm, the calculated dose at 0.5 cm depth exceeded the prescribed dose by ∼20%, while on the shielded side the dose increased by a factor of two, thus compromising the shielding efficiency of the original design. On the unshielded side of an outward-facing curved implant, the dose at 0.5 cm depth decreased by ∼20%. CONCLUSIONS When tumor bed curvature can be estimated from the preplanning CT scan, the results from this study provide quantitative guide for modifying the source strength to achieve the desired clinical results. In many intraoperative cases, however, accurate preplanning based on surface curvature may not be practical. In such situations, knowledge of the dosimetric impact of the surface curvature provides motivation for avoiding implantation geometries that can lead to either over/underdosing the target, or excess dose to healthy tissue.
Collapse
Affiliation(s)
- I Veltchev
- Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA
| | - R Price
- Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA
| | - X Chen
- Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA
| | - K Howell
- Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA
| | - J Meyer
- Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA
| | - C-M Ma
- Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA, 19111, USA
| |
Collapse
|
17
|
Schmid P, Pinder S, Wheatley D, Zummit C, Macaskill EJ, Hu J, Price R, Bundred N, Hadad S, Shia A, Sarker SJ, Lim L, Mousa K, O'Brien C, Wilson TR, Lackner MR, Gendreau S, Gazinska P, Korbie D, Trau M, Mainwaring P, Thompson A, Purushotham A. Abstract P2-08-02: Interaction of PIK3CA mutation subclasses with response to preoperative treatment with the PI3K inhibitor pictilisib in patients with estrogen receptor-positive breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-08-02] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Although preclinical data suggest that combining PI3K inhibitors with endocrine therapy may overcome resistance, results from randomized clinical trials have failed to identify a subgroup of patients that derive a substantial benefit. This preoperative window study assessed whether adding the PI3K inhibitor pictilisib can increase the anti-tumor effects of anastrozole in primary breast cancer and aimed to identify the most appropriate patient population for combination therapy.
Methods: In this randomized, open-label, phase 2 study, 167 postmenopausal women with newly diagnosed, operable, ER-positive, HER2-negative breast cancers were recruited. Participants were randomly allocated (2:1, favoring the combination) to two-weeks of preoperative treatment with anastrozole 1 mg once daily or the combination of anastrozole 1mg with pictilisib 260 mg once daily. The primary endpoint was inhibition of tumor cell proliferation, as measured by change in Ki-67 protein expression between tumor samples taken before and at the end of treatment. Secondary endpoints include induction of apoptosis (Caspase3) and safety. Comprehensive biomarkers analyses included targeted NGS of a comprehensive cancer panel of >400 genes (Ampliseq Comprehensive Cancer panel), copy number variation analyses, and pre- and post-treatment reverse-phase protein arrays (RPPA) and RNA profiling (NanoString nCounter platform).
Results:There was significantly greater geometric mean Ki67 suppression of 82.5% (90% CI, 78.3%-85.8%) for the combination vs 70.7% (61.0%-78.0%) for anastrozole [geometric mean ratio (combination/ anastrozole) 0.60 (0.58-0.85);p=0.01]. Higher baseline Ki67, Luminal B status and/or negative PR status were associated with increased benefit from adding pictilisib. A significant interaction was observed between PIK3CA mutation subtypes [helical domain mutations (HD), kinase domain mutations (KD), wildtype (WT)] and mean Ki67 suppression; the combination/anastrozole geometric mean ratio of Ki67 suppression was 0.48 (0.27-0.84; p=0.02) for patients with HD mutations and 0.63 (0.39–1.0; p=0.05) for patients with PIK3Ca WT, compared to 1.17 (0.57–2.41; p=0.64) for patients with KD mutations. This was largely due to patients with HD mutations showing a particularly poor response to anastrozole alone [mean Ki67 suppression 53.9% (9.5%-76.5%)], that was reversed by the addition of pictilisib [mean Ki-67 suppression 78.1% (71.0%-83.4%)]. On the other hand, patients with KD mutations responded well to anastrozole alone [mean Ki-67 suppression 77.7% (57.0%-88.4%)] and showed no benefit from the addition of pictilisib [mean Ki-67 suppression 73.9% (59.8%-83.0%)]. There was no significant difference in induction of apoptosis between treatment groups. Comprehensive pre- and post-treatment biomarkers analyses will be presented.
Conclusions: Adding pictilisib to anastrozole significantly increases the anti-proliferative response to preoperative treatment with anastrozole. A significant interaction was observed between PIK3CA mutation subtypes, with patients with helical domain mutations showing a particularly poor response to anastrozole alone that was reversed by the addition of pictilisib.
Citation Format: Schmid P, Pinder S, Wheatley D, Zummit C, Macaskill EJ, Hu J, Price R, Bundred N, Hadad S, Shia A, Sarker S-J, Lim L, Mousa K, O'Brien C, Wilson TR, Lackner MR, Gendreau S, Gazinska P, Korbie D, Trau M, Mainwaring P, Thompson A, Purushotham A. Interaction of PIK3CA mutation subclasses with response to preoperative treatment with the PI3K inhibitor pictilisib in patients with estrogen receptor-positive breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-08-02.
Collapse
Affiliation(s)
- P Schmid
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom; Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Barts Health NHS Trust, London, United Kingdom; King's College Hospital NHS Foundation Trust, London, United Kingdom; Manchester University NHS Foundation Trust, London, United Kingdom; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom; Genentech, San Francisco; Breast Cancer Now Research Unit, Cancer Centre at Guy's Hospital, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom; Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane City, Australia; Mater Research Centre, Brisbane, Australia; The University of Texas MD Anderson Cancer Centre, Houston
| | - S Pinder
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom; Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Barts Health NHS Trust, London, United Kingdom; King's College Hospital NHS Foundation Trust, London, United Kingdom; Manchester University NHS Foundation Trust, London, United Kingdom; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom; Genentech, San Francisco; Breast Cancer Now Research Unit, Cancer Centre at Guy's Hospital, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom; Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane City, Australia; Mater Research Centre, Brisbane, Australia; The University of Texas MD Anderson Cancer Centre, Houston
| | - D Wheatley
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom; Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Barts Health NHS Trust, London, United Kingdom; King's College Hospital NHS Foundation Trust, London, United Kingdom; Manchester University NHS Foundation Trust, London, United Kingdom; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom; Genentech, San Francisco; Breast Cancer Now Research Unit, Cancer Centre at Guy's Hospital, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom; Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane City, Australia; Mater Research Centre, Brisbane, Australia; The University of Texas MD Anderson Cancer Centre, Houston
| | - C Zummit
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom; Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Barts Health NHS Trust, London, United Kingdom; King's College Hospital NHS Foundation Trust, London, United Kingdom; Manchester University NHS Foundation Trust, London, United Kingdom; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom; Genentech, San Francisco; Breast Cancer Now Research Unit, Cancer Centre at Guy's Hospital, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom; Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane City, Australia; Mater Research Centre, Brisbane, Australia; The University of Texas MD Anderson Cancer Centre, Houston
| | - EJ Macaskill
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom; Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Barts Health NHS Trust, London, United Kingdom; King's College Hospital NHS Foundation Trust, London, United Kingdom; Manchester University NHS Foundation Trust, London, United Kingdom; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom; Genentech, San Francisco; Breast Cancer Now Research Unit, Cancer Centre at Guy's Hospital, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom; Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane City, Australia; Mater Research Centre, Brisbane, Australia; The University of Texas MD Anderson Cancer Centre, Houston
| | - J Hu
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom; Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Barts Health NHS Trust, London, United Kingdom; King's College Hospital NHS Foundation Trust, London, United Kingdom; Manchester University NHS Foundation Trust, London, United Kingdom; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom; Genentech, San Francisco; Breast Cancer Now Research Unit, Cancer Centre at Guy's Hospital, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom; Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane City, Australia; Mater Research Centre, Brisbane, Australia; The University of Texas MD Anderson Cancer Centre, Houston
| | - R Price
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom; Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Barts Health NHS Trust, London, United Kingdom; King's College Hospital NHS Foundation Trust, London, United Kingdom; Manchester University NHS Foundation Trust, London, United Kingdom; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom; Genentech, San Francisco; Breast Cancer Now Research Unit, Cancer Centre at Guy's Hospital, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom; Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane City, Australia; Mater Research Centre, Brisbane, Australia; The University of Texas MD Anderson Cancer Centre, Houston
| | - N Bundred
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom; Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Barts Health NHS Trust, London, United Kingdom; King's College Hospital NHS Foundation Trust, London, United Kingdom; Manchester University NHS Foundation Trust, London, United Kingdom; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom; Genentech, San Francisco; Breast Cancer Now Research Unit, Cancer Centre at Guy's Hospital, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom; Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane City, Australia; Mater Research Centre, Brisbane, Australia; The University of Texas MD Anderson Cancer Centre, Houston
| | - S Hadad
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom; Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Barts Health NHS Trust, London, United Kingdom; King's College Hospital NHS Foundation Trust, London, United Kingdom; Manchester University NHS Foundation Trust, London, United Kingdom; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom; Genentech, San Francisco; Breast Cancer Now Research Unit, Cancer Centre at Guy's Hospital, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom; Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane City, Australia; Mater Research Centre, Brisbane, Australia; The University of Texas MD Anderson Cancer Centre, Houston
| | - A Shia
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom; Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Barts Health NHS Trust, London, United Kingdom; King's College Hospital NHS Foundation Trust, London, United Kingdom; Manchester University NHS Foundation Trust, London, United Kingdom; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom; Genentech, San Francisco; Breast Cancer Now Research Unit, Cancer Centre at Guy's Hospital, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom; Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane City, Australia; Mater Research Centre, Brisbane, Australia; The University of Texas MD Anderson Cancer Centre, Houston
| | - S-J Sarker
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom; Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Barts Health NHS Trust, London, United Kingdom; King's College Hospital NHS Foundation Trust, London, United Kingdom; Manchester University NHS Foundation Trust, London, United Kingdom; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom; Genentech, San Francisco; Breast Cancer Now Research Unit, Cancer Centre at Guy's Hospital, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom; Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane City, Australia; Mater Research Centre, Brisbane, Australia; The University of Texas MD Anderson Cancer Centre, Houston
| | - L Lim
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom; Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Barts Health NHS Trust, London, United Kingdom; King's College Hospital NHS Foundation Trust, London, United Kingdom; Manchester University NHS Foundation Trust, London, United Kingdom; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom; Genentech, San Francisco; Breast Cancer Now Research Unit, Cancer Centre at Guy's Hospital, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom; Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane City, Australia; Mater Research Centre, Brisbane, Australia; The University of Texas MD Anderson Cancer Centre, Houston
| | - K Mousa
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom; Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Barts Health NHS Trust, London, United Kingdom; King's College Hospital NHS Foundation Trust, London, United Kingdom; Manchester University NHS Foundation Trust, London, United Kingdom; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom; Genentech, San Francisco; Breast Cancer Now Research Unit, Cancer Centre at Guy's Hospital, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom; Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane City, Australia; Mater Research Centre, Brisbane, Australia; The University of Texas MD Anderson Cancer Centre, Houston
| | - C O'Brien
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom; Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Barts Health NHS Trust, London, United Kingdom; King's College Hospital NHS Foundation Trust, London, United Kingdom; Manchester University NHS Foundation Trust, London, United Kingdom; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom; Genentech, San Francisco; Breast Cancer Now Research Unit, Cancer Centre at Guy's Hospital, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom; Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane City, Australia; Mater Research Centre, Brisbane, Australia; The University of Texas MD Anderson Cancer Centre, Houston
| | - TR Wilson
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom; Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Barts Health NHS Trust, London, United Kingdom; King's College Hospital NHS Foundation Trust, London, United Kingdom; Manchester University NHS Foundation Trust, London, United Kingdom; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom; Genentech, San Francisco; Breast Cancer Now Research Unit, Cancer Centre at Guy's Hospital, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom; Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane City, Australia; Mater Research Centre, Brisbane, Australia; The University of Texas MD Anderson Cancer Centre, Houston
| | - MR Lackner
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom; Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Barts Health NHS Trust, London, United Kingdom; King's College Hospital NHS Foundation Trust, London, United Kingdom; Manchester University NHS Foundation Trust, London, United Kingdom; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom; Genentech, San Francisco; Breast Cancer Now Research Unit, Cancer Centre at Guy's Hospital, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom; Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane City, Australia; Mater Research Centre, Brisbane, Australia; The University of Texas MD Anderson Cancer Centre, Houston
| | - S Gendreau
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom; Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Barts Health NHS Trust, London, United Kingdom; King's College Hospital NHS Foundation Trust, London, United Kingdom; Manchester University NHS Foundation Trust, London, United Kingdom; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom; Genentech, San Francisco; Breast Cancer Now Research Unit, Cancer Centre at Guy's Hospital, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom; Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane City, Australia; Mater Research Centre, Brisbane, Australia; The University of Texas MD Anderson Cancer Centre, Houston
| | - P Gazinska
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom; Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Barts Health NHS Trust, London, United Kingdom; King's College Hospital NHS Foundation Trust, London, United Kingdom; Manchester University NHS Foundation Trust, London, United Kingdom; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom; Genentech, San Francisco; Breast Cancer Now Research Unit, Cancer Centre at Guy's Hospital, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom; Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane City, Australia; Mater Research Centre, Brisbane, Australia; The University of Texas MD Anderson Cancer Centre, Houston
| | - D Korbie
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom; Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Barts Health NHS Trust, London, United Kingdom; King's College Hospital NHS Foundation Trust, London, United Kingdom; Manchester University NHS Foundation Trust, London, United Kingdom; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom; Genentech, San Francisco; Breast Cancer Now Research Unit, Cancer Centre at Guy's Hospital, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom; Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane City, Australia; Mater Research Centre, Brisbane, Australia; The University of Texas MD Anderson Cancer Centre, Houston
| | - M Trau
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom; Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Barts Health NHS Trust, London, United Kingdom; King's College Hospital NHS Foundation Trust, London, United Kingdom; Manchester University NHS Foundation Trust, London, United Kingdom; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom; Genentech, San Francisco; Breast Cancer Now Research Unit, Cancer Centre at Guy's Hospital, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom; Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane City, Australia; Mater Research Centre, Brisbane, Australia; The University of Texas MD Anderson Cancer Centre, Houston
| | - P Mainwaring
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom; Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Barts Health NHS Trust, London, United Kingdom; King's College Hospital NHS Foundation Trust, London, United Kingdom; Manchester University NHS Foundation Trust, London, United Kingdom; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom; Genentech, San Francisco; Breast Cancer Now Research Unit, Cancer Centre at Guy's Hospital, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom; Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane City, Australia; Mater Research Centre, Brisbane, Australia; The University of Texas MD Anderson Cancer Centre, Houston
| | - A Thompson
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom; Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Barts Health NHS Trust, London, United Kingdom; King's College Hospital NHS Foundation Trust, London, United Kingdom; Manchester University NHS Foundation Trust, London, United Kingdom; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom; Genentech, San Francisco; Breast Cancer Now Research Unit, Cancer Centre at Guy's Hospital, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom; Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane City, Australia; Mater Research Centre, Brisbane, Australia; The University of Texas MD Anderson Cancer Centre, Houston
| | - A Purushotham
- Barts Cancer Institute, Queen Mary University of London, London, United Kingdom; Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; Royal Cornwall Hospitals NHS Trust, Truro, United Kingdom; Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom; Ninewells Hospital, Dundee, United Kingdom; Barts Health NHS Trust, London, United Kingdom; King's College Hospital NHS Foundation Trust, London, United Kingdom; Manchester University NHS Foundation Trust, London, United Kingdom; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom; Genentech, San Francisco; Breast Cancer Now Research Unit, Cancer Centre at Guy's Hospital, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom; Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Brisbane City, Australia; Mater Research Centre, Brisbane, Australia; The University of Texas MD Anderson Cancer Centre, Houston
| |
Collapse
|
18
|
Lievens Y, Aggarwal A, Audisio R, Banks I, Collette L, de Vries E, Grau C, Price R, Kathy O. Value based locoregional cancer treatment: the ECCO VBHC project. Eur J Surg Oncol 2019. [DOI: 10.1016/j.ejso.2018.10.073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
19
|
Gupta A, Pouliquen I, Steinfeld J, Price R, Austin D, Bradford E, Yancey S, Gruber A. La pharmacocinétique et la pharmacodynamie du mépolizumab chez les enfants âgés entre 6 et 11 ans avec un asthme sévère éosinophilique. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
20
|
Hazarika R, Albreht T, Berger B, Duplay D, Makaroff L, Maravic Z, Mortuza R, Muthu V, Oliver K, Price R, van Meerveld M, Steinmann K, Krukowsk A, Catena R, Wait S, Zilli V. Improving value for cancer patients: A European study of outcomes in practice. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy303.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
Byrne H, Shah N, Price R. A review of pre-operative Anticoagulant (AC) and Antiplatelet (AP) prescribing in a plastic surgery Outpatient Local Anaesthetic Clinic (OPLA). Int J Surg 2018. [DOI: 10.1016/j.ijsu.2018.05.436] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
22
|
Stahovich M, Lerum S, Price R, Chillcott S, Adamson R, Dembitsky W. Family Participation in Daily ECMO Rounds. J Heart Lung Transplant 2018. [DOI: 10.1016/j.healun.2018.01.461] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
23
|
|
24
|
Lombardo S, Unurbileg B, Gerelmaa J, Bayarbaatar L, Sarnai E, Price R. Trauma Care in Mongolia: INTACT Evaluation and Recommendations for Improvement. World J Surg 2018; 42:2285-2292. [DOI: 10.1007/s00268-018-4462-8] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
25
|
Devine OP, Harborne AC, Lo WB, Price R. Colonic perforation by an intrathecal baclofen pump catheter causing delayed Escherichia coli meningitis. BMJ Case Rep 2017; 2017:bcr-2017-222539. [PMID: 29269368 DOI: 10.1136/bcr-2017-222539] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Intrathecal baclofen (ITB) delivery via an implanted pump is frequently used for the treatment of spasticity. This is an effective and safe neurosurgical and pharmacological intervention associated with an improvement in patient quality of life. There is, however, a risk of device-related infection. We present a patient with pump-site infection and Escherichia coli meningitis secondary to transcolonic perforation of an intrathecal baclofen pump catheter. While this is rare, we review the intraoperative precautions and best practices that should be taken to prevent and manage this unusual complication.
Collapse
Affiliation(s)
| | | | - William B Lo
- Queen Elizabeth Hospital Birmingham, Birmingham, UK
| | - Rupert Price
- Royal Stoke University Hospital, Stoke-on-Trent, Staffordshire, UK
| |
Collapse
|
26
|
Ortega H, Albers F, Llanos-Ackert J, Bradford E, Price R, Pouliquen I, Castro M. P506 Impact of weight on the efficacy of mepolizumab in patients with severe eosinophilic asthma. Ann Allergy Asthma Immunol 2017. [DOI: 10.1016/j.anai.2017.09.072] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
27
|
Katial R, Albers F, Prazma C, Bradford E, Ortega H, Price R, Pouliquen I, Castro M. P505 Impact of weight on steroid reduction in patients with severe eosinophilic asthma treated with mepolizumab. Ann Allergy Asthma Immunol 2017. [DOI: 10.1016/j.anai.2017.09.071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
28
|
Birch S, Price R, Andreou P, Jones G, Portolesi A. Variations in survival time for amalgam and resin composite restorations: a population based cohort analysis. Community Dent Health 2017; 33:208-212. [PMID: 28509516 DOI: 10.1922/cdh_3825birch05] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 08/06/2015] [Accepted: 02/01/2016] [Indexed: 11/11/2022]
Abstract
OBJECTIVE To estimate the association between the restorative material used and time to further treatment across population cohorts with universal coverage for dental treatment. BASIC RESEARCH DESIGN Cohort study of variation in survival time for tooth restorations over time and by restoration material used based on an Accelerated Failure Time model. CLINICAL SETTING Primary dental care clinics. PARTICIPANTS Members of Canada's First Nations and Inuit population covered by the Non-Insured Health Benefits program of Health Canada for the period April 1, 1999 to March 31, 2012. INTERVENTION Tooth restorations using resin composite or amalgam material. MAIN OUTCOME Survival time of restoration to further treatment. RESULTS Median survival time for resin composite was 51 days longer than amalgam, for restorations placed in 1999-2000. This difference was not statistically significant (p⟩0.05). Median survival times were lower for females, older subjects. Those visiting the dentist annually, and decreased monotonically over time from 11.2 and 11.3 years for resin composite and amalgam restorations respectively placed in 1999-2000 to 6.9 and 7.0 years for those placed in 2009-10. CONCLUSIONS Resin composite restorations performed no better than amalgams over the study period, but cost considerably more. With the combination of the overall decrease in survival times for both resin composite and amalgam restorations and the increase in use of resin composite, the costs of serving Health Canada's Non-Insured Health Benefits population will rise considerably, even without any increase in the incidence of caries.
Collapse
Affiliation(s)
- S Birch
- Centre for Health Economics and Policy Analysis McMaster University, Hamilton, Ontario, Canada
| | - R Price
- Department of Dental Clinical Sciences, Dalhousie University, Halifax, Nova Scotia, Canada
| | - P Andreou
- Department of Community Health and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada
| | - G Jones
- First Nations and Inuit Health Branch, Atlantic Region, Health Canada, Halifax, Nova Scotia, Canada
| | - A Portolesi
- Health Canada, First Nations and Inuit Health Branch, Ottawa, Canada
| |
Collapse
|
29
|
Pérez-Díaz I, Hayes J, Medina E, Anekella K, Daughtry K, Dieck S, Levi M, Price R, Butz N, Lu Z, Azcarate-Peril M. Reassessment of the succession of lactic acid bacteria in commercial cucumber fermentations and physiological and genomic features associated with their dominance. Food Microbiol 2017; 63:217-227. [DOI: 10.1016/j.fm.2016.11.025] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2016] [Revised: 11/04/2016] [Accepted: 11/30/2016] [Indexed: 10/20/2022]
|
30
|
Batistoni P, Popovichev S, Crowe R, Cufar A, Ghani Z, Keogh K, Peacock A, Price R, Baranov A, Korotkov S, Lykin P, Samoshin A. Technical preparations for the in-vessel 14 MeV neutron calibration at JET. Fusion Engineering and Design 2017. [DOI: 10.1016/j.fusengdes.2017.01.023] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
31
|
Price R. Misinterpreting the p value. Anaesthesia 2017; 72:546-547. [DOI: 10.1111/anae.13855] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- R. Price
- Royal Devon and Exeter Hospital; Exeter UK
| |
Collapse
|
32
|
Tiao J, Feng R, Bird S, Choi JK, Dunham J, George M, Gonzalez-Rivera TC, Kaufman JL, Khan N, Luo JJ, Micheletti R, Payne AS, Price R, Quinn C, Rubin AI, Sreih AG, Thomas P, Okawa J, Werth VP. The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) among dermatologists, rheumatologists and neurologists. Br J Dermatol 2016; 176:423-430. [PMID: 28004387 DOI: 10.1111/bjd.15140] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/13/2016] [Indexed: 11/30/2022]
Abstract
BACKGROUND Previous studies have shown that skin disease in dermatomyositis (DM) is best assessed using the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI). Although the CDASI has been validated for use by dermatologists, it has not been validated for use by other physicians such as rheumatologists and neurologists, who also manage patients with DM and assess skin activity in clinical trials. OBJECTIVES To assess the reliability of the CDASI among dermatologists, rheumatologists and neurologists. METHODS Fifteen patients with cutaneous DM were assessed using the CDASI and the Physician Global Assessment (PGA) by five dermatologists, five rheumatologists and five neurologists. RESULTS The mean CDASI activity scores for dermatologists, rheumatologists and neurologists were 21·0, 21·8 and 20·8, respectively. These mean scores were not different among the specialists. The CDASI damage score means for dermatologists, rheumatologists and neurologists were 5·3, 7·0 and 4·8, respectively. The mean scores between dermatologists and rheumatologists were significantly different, but the means between dermatologists and neurologists were not. The intraclass correlation coefficients (ICCs) for interrater reliability for CDASI activity and damage were good to excellent for dermatologists and rheumatologists, and moderate to excellent for neurologists. The ICCs for intrarater reliability for CDASI activity and damage were excellent for dermatologists and rheumatologists and moderate to excellent for neurologists. The PGA displayed lower interrater and intrarater reliability relative to the CDASI. CONCLUSIONS Our results confirm the reliability of the CDASI when used by dermatologists and rheumatologists. The data for its use by neurologists were not as robust.
Collapse
Affiliation(s)
- J Tiao
- Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, U.S.A.,Corporal Michael J. Crescenz Veterans Affairs Medical Center (Philadelphia), Philadelphia, PA, U.S.A
| | - R Feng
- Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, U.S.A
| | - S Bird
- Department of Neurology Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, U.S.A
| | - J K Choi
- Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, U.S.A.,Corporal Michael J. Crescenz Veterans Affairs Medical Center (Philadelphia), Philadelphia, PA, U.S.A
| | - J Dunham
- Division of Rheumatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, U.S.A
| | - M George
- Division of Rheumatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, U.S.A
| | - T C Gonzalez-Rivera
- Division of Rheumatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, U.S.A.,Department of Neurology, GlaxoSmithKline USA, Philadelphia, PA, U.S.A
| | - J L Kaufman
- Department of Neurology Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, U.S.A
| | - N Khan
- Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, U.S.A.,Corporal Michael J. Crescenz Veterans Affairs Medical Center (Philadelphia), Philadelphia, PA, U.S.A
| | - J J Luo
- Department of Neurology, Temple University School of Medicine, Philadelphia, PA, U.S.A
| | - R Micheletti
- Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, U.S.A
| | - A S Payne
- Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, U.S.A
| | - R Price
- Department of Neurology Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, U.S.A
| | - C Quinn
- Department of Neurology Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, U.S.A
| | - A I Rubin
- Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, U.S.A
| | - A G Sreih
- Division of Rheumatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, U.S.A
| | - P Thomas
- Division of Rheumatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, U.S.A
| | - J Okawa
- Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, U.S.A
| | - V P Werth
- Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, U.S.A.,Corporal Michael J. Crescenz Veterans Affairs Medical Center (Philadelphia), Philadelphia, PA, U.S.A
| |
Collapse
|
33
|
Price R, Okamoto M, Le Huec JC, Hasegawa K. Normative spino-pelvic parameters in patients with the lumbarization of S1 compared to a normal asymptomatic population. Eur Spine J 2016; 25:3694-3698. [DOI: 10.1007/s00586-016-4794-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/24/2016] [Revised: 08/06/2016] [Accepted: 09/20/2016] [Indexed: 11/24/2022]
|
34
|
Price R, Graham C, Ramalingam S. Does a chill cause a cold? J Clin Virol 2016. [DOI: 10.1016/j.jcv.2016.08.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
35
|
Weldon J, Price R. Skeletal survey quality in non-accidental injury – A single site evaluation of the effects of imaging checklists. Radiography (Lond) 2016. [DOI: 10.1016/j.radi.2016.04.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
36
|
Affiliation(s)
- R. Price
- Mechanical Recorder/CPI Group LEIGH INSTRUMENTS LIMITED
| |
Collapse
|
37
|
Eldib A, Chibani O, Chen L, Li J, Price R, Ma C. SU-F-T-524: Investigation of the Dosimertric Benefits of Interchangeable Source Size of a Novel Rotating Gamma System. Med Phys 2016. [DOI: 10.1118/1.4956709] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
38
|
Carver D, Kost S, Segars P, Fraser N, Pickens D, Price R, Stabin M. TH-AB-207A-06: The Use of Realistic Phantoms to Predict CT Dose to Pediatric Patients. Med Phys 2016. [DOI: 10.1118/1.4958082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
39
|
Fan J, Lin T, Jin L, Chen L, Veltchev I, Wang L, Eldib A, Chibani O, Wang B, Xu Q, Price R, Ma C. MO-FG-CAMPUS-JeP3-05: Evaluation of 4D CT-On-Rails Target Localization Methods for Free Breathing Liver Stereotactic Body Radiotherapy (SBRT). Med Phys 2016. [DOI: 10.1118/1.4957380] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
40
|
Price R, Veltchev I, Lin T, Gleason R, Ma C. SU-F-T-345: Quasi-Dead Beams: Clinical Relevance and Implications for Automatic Planning. Med Phys 2016. [DOI: 10.1118/1.4956530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
41
|
Jin L, Fan J, Eldib A, Price R, Ma C. SU-F-T-81: Treating Nose Skin Using Energy and Intensity Modulated Electron Beams with Monte Carlo Based Dose Calculation. Med Phys 2016. [DOI: 10.1118/1.4956217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
42
|
Veltchev I, Price R, Anderson P, Ma C. SU-F-T-07: Dosimetric Impact of the Dwell Position Inaccuracy in HDR Ring and Tandem Treatments with VarisourceIX Afterloader. Med Phys 2016. [DOI: 10.1118/1.4956141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
43
|
Veltchev I, Price R, Horwitz E, Ma C. SU-F-T-34: Transition Form CT-Based to Ultrasound-Based HDR Treatment Planning for Prostate Cancer. Med Phys 2016. [DOI: 10.1118/1.4956169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
44
|
Miller L, Hicks B, Price R, Higgs A. Corrigendum to “The introduction, deployment and impact of assistant practitioners in diagnostic radiography in Scotland” [Radiography 21 (2015) 141–145]. Radiography (Lond) 2016. [DOI: 10.1016/j.radi.2015.12.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
45
|
Wells KM, Shalabi H, Sergelen O, Wiessner P, Zhang C, deVries C, Price R. Patient and Physician Perceptions of Changes in Surgical Care in Mongolia 9 Years After Roll-out of a National Training Program for Laparoscopy. World J Surg 2016; 40:1859-64. [DOI: 10.1007/s00268-016-3498-x] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
46
|
Schmid P, Pinder SE, Bundred N, Wheatley D, Macaskill J, Zammit C, Hu J, Price R, Shia A, Lim L, Parker P, Molinero L, Yu J, O'Brien C, Wilson T, Savage H, Derynck M, Lackner MR, Amler L, Purushotham A, Thompson A, Gendreau S. Abstract P5-13-01: Transcript analysis of PI3K and immune-related genes and gene signatures in the pre- and post-treatment samples from the window of opportunity study of anastrozole and anastrozole with pictilisib (GDC-0941) in patients with HR-positive early breast cancer (OPPORTUNE study). Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p5-13-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The OPPORTUNE Study randomized postmenopausal patients (pts) to receive 2-week preoperative treatment with anastrozole (ANA) plus pictilisib ("ANA+PIC" arm) or ANA alone. Patients had newly diagnosed, operable, ER+, HER2- invasive breast cancer of ≥1 cm size. The primary outcome at interim analysis (n=70) revealed that the addition of PIC significantly increased the anti-proliferative response to ANA as measured by reduction in Ki67 immunohistochemistry (IHC). Multivariate analyses suggested benefit of PIC for patients with luminal B disease (Schmid et al. SABCS 2014).
Methods: RNA expression analysis of ∼800 breast cancer-related genes was performed on patients analyzed at the interim analysis, including 14 (ANA) and 20 (ANA+PIC) patients with matched pre- and post- treatment paired tumour samples using the nCounter platform (NanoString). Differential expression of individual genes by arm was assessed using paired and moderated t-tests and statistical significance assessed through false discovery rate (FDR). Ingenuity Pathway Analysis (IPA) of differentially expressed transcripts identified pathways of relevance. Protein expression was analyzed by reverse protein array ( RPPA) in pre- and post-treatment samples.
Results: In an unsupervised analysis, down-regulation of genes associated with ER signaling was observed in patients who received single-agent ANA and ANA+PIC, which included genes that regulate the cell cycle, cell death, survival, growth and proliferation and known ER target genes (e.g., PGR, GREB1). In addition, transcripts related to growth factor signaling pathway appeared to be specifically modulated in the ANA+PIC arm, possibly via the upregulation of the expression of RTK ligands. There were no clear changes in PI3K-related phosphoproteins (e.g., AKT, S6, 4E-BP1) in the post-treatment samples by RPPA. However, known PI3K-regulated genes, IRS2 and PIK3IP1, were upregulated in the post-treatment samples and a composite PI3K gene expression signature score (O'Brien et al. 2010) was reduced in both study arms following treatment. This PI3K signature was associated with pre-treatment luminal B status (n=27) and, consistent with this finding, the baseline PI3K gene signature score in the ANA arm, but not the ANA+PIC arm, was inversely associated with the decrease in post treatment Ki67. The tumor immune microenvironment was analyzed though the use of composite gene sets. In our initial observations, analysis of pre- and post-treatment samples showed that 2-week treatment with ANA resulted in a modest increase in transcripts associated with multiple immune signatures, which was further enhanced by the addition of PIC.
Conclusions: Gene expression analysis of pre- and post-treatment samples in the OPPORTUNE study demonstrates on-target inhibition of ER and PI3K signaling networks. The analysis of additional paired samples is in progress to further assess if 2-weeks of treatment with a regimen containing an AI in patients with early breast cancer impacts the tumor immune microenvironment.
Citation Format: Schmid P, Pinder SE, Bundred N, Wheatley D, Macaskill J, Zammit C, Hu J, Price R, Shia A, Lim L, Parker P, Molinero L, Yu J, O'Brien C, Wilson T, Savage H, Derynck M, Lackner MR, Amler L, Purushotham A, Thompson A, Gendreau S. Transcript analysis of PI3K and immune-related genes and gene signatures in the pre- and post-treatment samples from the window of opportunity study of anastrozole and anastrozole with pictilisib (GDC-0941) in patients with HR-positive early breast cancer (OPPORTUNE study). [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P5-13-01.
Collapse
Affiliation(s)
- P Schmid
- Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Kings College London, London, United Kingdom; Guys and St Thomas NHS Trust, Kings College London, London, United Kingdom; University Hospital of South Manchester, Manchester, United Kingdom; Royal Cornwall Hospital, Truro, United Kingdom; Ninewells Hospital Dundee, Dundee, United Kingdom; Brighton and Sussex University Hospital NHS Trust, Brighton, United Kingdom; Barts Health NHS Trust, London, United Kingdom; Kings College Hospital, London, United Kingdom; MD Anderson Cancer Centre, Houston, TX; Genentech, South San Francisco, California, South San Francisco, CA
| | - SE Pinder
- Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Kings College London, London, United Kingdom; Guys and St Thomas NHS Trust, Kings College London, London, United Kingdom; University Hospital of South Manchester, Manchester, United Kingdom; Royal Cornwall Hospital, Truro, United Kingdom; Ninewells Hospital Dundee, Dundee, United Kingdom; Brighton and Sussex University Hospital NHS Trust, Brighton, United Kingdom; Barts Health NHS Trust, London, United Kingdom; Kings College Hospital, London, United Kingdom; MD Anderson Cancer Centre, Houston, TX; Genentech, South San Francisco, California, South San Francisco, CA
| | - N Bundred
- Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Kings College London, London, United Kingdom; Guys and St Thomas NHS Trust, Kings College London, London, United Kingdom; University Hospital of South Manchester, Manchester, United Kingdom; Royal Cornwall Hospital, Truro, United Kingdom; Ninewells Hospital Dundee, Dundee, United Kingdom; Brighton and Sussex University Hospital NHS Trust, Brighton, United Kingdom; Barts Health NHS Trust, London, United Kingdom; Kings College Hospital, London, United Kingdom; MD Anderson Cancer Centre, Houston, TX; Genentech, South San Francisco, California, South San Francisco, CA
| | - D Wheatley
- Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Kings College London, London, United Kingdom; Guys and St Thomas NHS Trust, Kings College London, London, United Kingdom; University Hospital of South Manchester, Manchester, United Kingdom; Royal Cornwall Hospital, Truro, United Kingdom; Ninewells Hospital Dundee, Dundee, United Kingdom; Brighton and Sussex University Hospital NHS Trust, Brighton, United Kingdom; Barts Health NHS Trust, London, United Kingdom; Kings College Hospital, London, United Kingdom; MD Anderson Cancer Centre, Houston, TX; Genentech, South San Francisco, California, South San Francisco, CA
| | - J Macaskill
- Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Kings College London, London, United Kingdom; Guys and St Thomas NHS Trust, Kings College London, London, United Kingdom; University Hospital of South Manchester, Manchester, United Kingdom; Royal Cornwall Hospital, Truro, United Kingdom; Ninewells Hospital Dundee, Dundee, United Kingdom; Brighton and Sussex University Hospital NHS Trust, Brighton, United Kingdom; Barts Health NHS Trust, London, United Kingdom; Kings College Hospital, London, United Kingdom; MD Anderson Cancer Centre, Houston, TX; Genentech, South San Francisco, California, South San Francisco, CA
| | - C Zammit
- Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Kings College London, London, United Kingdom; Guys and St Thomas NHS Trust, Kings College London, London, United Kingdom; University Hospital of South Manchester, Manchester, United Kingdom; Royal Cornwall Hospital, Truro, United Kingdom; Ninewells Hospital Dundee, Dundee, United Kingdom; Brighton and Sussex University Hospital NHS Trust, Brighton, United Kingdom; Barts Health NHS Trust, London, United Kingdom; Kings College Hospital, London, United Kingdom; MD Anderson Cancer Centre, Houston, TX; Genentech, South San Francisco, California, South San Francisco, CA
| | - J Hu
- Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Kings College London, London, United Kingdom; Guys and St Thomas NHS Trust, Kings College London, London, United Kingdom; University Hospital of South Manchester, Manchester, United Kingdom; Royal Cornwall Hospital, Truro, United Kingdom; Ninewells Hospital Dundee, Dundee, United Kingdom; Brighton and Sussex University Hospital NHS Trust, Brighton, United Kingdom; Barts Health NHS Trust, London, United Kingdom; Kings College Hospital, London, United Kingdom; MD Anderson Cancer Centre, Houston, TX; Genentech, South San Francisco, California, South San Francisco, CA
| | - R Price
- Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Kings College London, London, United Kingdom; Guys and St Thomas NHS Trust, Kings College London, London, United Kingdom; University Hospital of South Manchester, Manchester, United Kingdom; Royal Cornwall Hospital, Truro, United Kingdom; Ninewells Hospital Dundee, Dundee, United Kingdom; Brighton and Sussex University Hospital NHS Trust, Brighton, United Kingdom; Barts Health NHS Trust, London, United Kingdom; Kings College Hospital, London, United Kingdom; MD Anderson Cancer Centre, Houston, TX; Genentech, South San Francisco, California, South San Francisco, CA
| | - A Shia
- Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Kings College London, London, United Kingdom; Guys and St Thomas NHS Trust, Kings College London, London, United Kingdom; University Hospital of South Manchester, Manchester, United Kingdom; Royal Cornwall Hospital, Truro, United Kingdom; Ninewells Hospital Dundee, Dundee, United Kingdom; Brighton and Sussex University Hospital NHS Trust, Brighton, United Kingdom; Barts Health NHS Trust, London, United Kingdom; Kings College Hospital, London, United Kingdom; MD Anderson Cancer Centre, Houston, TX; Genentech, South San Francisco, California, South San Francisco, CA
| | - L Lim
- Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Kings College London, London, United Kingdom; Guys and St Thomas NHS Trust, Kings College London, London, United Kingdom; University Hospital of South Manchester, Manchester, United Kingdom; Royal Cornwall Hospital, Truro, United Kingdom; Ninewells Hospital Dundee, Dundee, United Kingdom; Brighton and Sussex University Hospital NHS Trust, Brighton, United Kingdom; Barts Health NHS Trust, London, United Kingdom; Kings College Hospital, London, United Kingdom; MD Anderson Cancer Centre, Houston, TX; Genentech, South San Francisco, California, South San Francisco, CA
| | - P Parker
- Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Kings College London, London, United Kingdom; Guys and St Thomas NHS Trust, Kings College London, London, United Kingdom; University Hospital of South Manchester, Manchester, United Kingdom; Royal Cornwall Hospital, Truro, United Kingdom; Ninewells Hospital Dundee, Dundee, United Kingdom; Brighton and Sussex University Hospital NHS Trust, Brighton, United Kingdom; Barts Health NHS Trust, London, United Kingdom; Kings College Hospital, London, United Kingdom; MD Anderson Cancer Centre, Houston, TX; Genentech, South San Francisco, California, South San Francisco, CA
| | - L Molinero
- Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Kings College London, London, United Kingdom; Guys and St Thomas NHS Trust, Kings College London, London, United Kingdom; University Hospital of South Manchester, Manchester, United Kingdom; Royal Cornwall Hospital, Truro, United Kingdom; Ninewells Hospital Dundee, Dundee, United Kingdom; Brighton and Sussex University Hospital NHS Trust, Brighton, United Kingdom; Barts Health NHS Trust, London, United Kingdom; Kings College Hospital, London, United Kingdom; MD Anderson Cancer Centre, Houston, TX; Genentech, South San Francisco, California, South San Francisco, CA
| | - J Yu
- Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Kings College London, London, United Kingdom; Guys and St Thomas NHS Trust, Kings College London, London, United Kingdom; University Hospital of South Manchester, Manchester, United Kingdom; Royal Cornwall Hospital, Truro, United Kingdom; Ninewells Hospital Dundee, Dundee, United Kingdom; Brighton and Sussex University Hospital NHS Trust, Brighton, United Kingdom; Barts Health NHS Trust, London, United Kingdom; Kings College Hospital, London, United Kingdom; MD Anderson Cancer Centre, Houston, TX; Genentech, South San Francisco, California, South San Francisco, CA
| | - C O'Brien
- Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Kings College London, London, United Kingdom; Guys and St Thomas NHS Trust, Kings College London, London, United Kingdom; University Hospital of South Manchester, Manchester, United Kingdom; Royal Cornwall Hospital, Truro, United Kingdom; Ninewells Hospital Dundee, Dundee, United Kingdom; Brighton and Sussex University Hospital NHS Trust, Brighton, United Kingdom; Barts Health NHS Trust, London, United Kingdom; Kings College Hospital, London, United Kingdom; MD Anderson Cancer Centre, Houston, TX; Genentech, South San Francisco, California, South San Francisco, CA
| | - T Wilson
- Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Kings College London, London, United Kingdom; Guys and St Thomas NHS Trust, Kings College London, London, United Kingdom; University Hospital of South Manchester, Manchester, United Kingdom; Royal Cornwall Hospital, Truro, United Kingdom; Ninewells Hospital Dundee, Dundee, United Kingdom; Brighton and Sussex University Hospital NHS Trust, Brighton, United Kingdom; Barts Health NHS Trust, London, United Kingdom; Kings College Hospital, London, United Kingdom; MD Anderson Cancer Centre, Houston, TX; Genentech, South San Francisco, California, South San Francisco, CA
| | - H Savage
- Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Kings College London, London, United Kingdom; Guys and St Thomas NHS Trust, Kings College London, London, United Kingdom; University Hospital of South Manchester, Manchester, United Kingdom; Royal Cornwall Hospital, Truro, United Kingdom; Ninewells Hospital Dundee, Dundee, United Kingdom; Brighton and Sussex University Hospital NHS Trust, Brighton, United Kingdom; Barts Health NHS Trust, London, United Kingdom; Kings College Hospital, London, United Kingdom; MD Anderson Cancer Centre, Houston, TX; Genentech, South San Francisco, California, South San Francisco, CA
| | - M Derynck
- Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Kings College London, London, United Kingdom; Guys and St Thomas NHS Trust, Kings College London, London, United Kingdom; University Hospital of South Manchester, Manchester, United Kingdom; Royal Cornwall Hospital, Truro, United Kingdom; Ninewells Hospital Dundee, Dundee, United Kingdom; Brighton and Sussex University Hospital NHS Trust, Brighton, United Kingdom; Barts Health NHS Trust, London, United Kingdom; Kings College Hospital, London, United Kingdom; MD Anderson Cancer Centre, Houston, TX; Genentech, South San Francisco, California, South San Francisco, CA
| | - MR Lackner
- Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Kings College London, London, United Kingdom; Guys and St Thomas NHS Trust, Kings College London, London, United Kingdom; University Hospital of South Manchester, Manchester, United Kingdom; Royal Cornwall Hospital, Truro, United Kingdom; Ninewells Hospital Dundee, Dundee, United Kingdom; Brighton and Sussex University Hospital NHS Trust, Brighton, United Kingdom; Barts Health NHS Trust, London, United Kingdom; Kings College Hospital, London, United Kingdom; MD Anderson Cancer Centre, Houston, TX; Genentech, South San Francisco, California, South San Francisco, CA
| | - L Amler
- Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Kings College London, London, United Kingdom; Guys and St Thomas NHS Trust, Kings College London, London, United Kingdom; University Hospital of South Manchester, Manchester, United Kingdom; Royal Cornwall Hospital, Truro, United Kingdom; Ninewells Hospital Dundee, Dundee, United Kingdom; Brighton and Sussex University Hospital NHS Trust, Brighton, United Kingdom; Barts Health NHS Trust, London, United Kingdom; Kings College Hospital, London, United Kingdom; MD Anderson Cancer Centre, Houston, TX; Genentech, South San Francisco, California, South San Francisco, CA
| | - A Purushotham
- Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Kings College London, London, United Kingdom; Guys and St Thomas NHS Trust, Kings College London, London, United Kingdom; University Hospital of South Manchester, Manchester, United Kingdom; Royal Cornwall Hospital, Truro, United Kingdom; Ninewells Hospital Dundee, Dundee, United Kingdom; Brighton and Sussex University Hospital NHS Trust, Brighton, United Kingdom; Barts Health NHS Trust, London, United Kingdom; Kings College Hospital, London, United Kingdom; MD Anderson Cancer Centre, Houston, TX; Genentech, South San Francisco, California, South San Francisco, CA
| | - A Thompson
- Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Kings College London, London, United Kingdom; Guys and St Thomas NHS Trust, Kings College London, London, United Kingdom; University Hospital of South Manchester, Manchester, United Kingdom; Royal Cornwall Hospital, Truro, United Kingdom; Ninewells Hospital Dundee, Dundee, United Kingdom; Brighton and Sussex University Hospital NHS Trust, Brighton, United Kingdom; Barts Health NHS Trust, London, United Kingdom; Kings College Hospital, London, United Kingdom; MD Anderson Cancer Centre, Houston, TX; Genentech, South San Francisco, California, South San Francisco, CA
| | - S Gendreau
- Barts Cancer Institute, Queen Mary University London, London, United Kingdom; Kings College London, London, United Kingdom; Guys and St Thomas NHS Trust, Kings College London, London, United Kingdom; University Hospital of South Manchester, Manchester, United Kingdom; Royal Cornwall Hospital, Truro, United Kingdom; Ninewells Hospital Dundee, Dundee, United Kingdom; Brighton and Sussex University Hospital NHS Trust, Brighton, United Kingdom; Barts Health NHS Trust, London, United Kingdom; Kings College Hospital, London, United Kingdom; MD Anderson Cancer Centre, Houston, TX; Genentech, South San Francisco, California, South San Francisco, CA
| |
Collapse
|
47
|
Albers F, Bourdin A, Price R, Yancey S, Prazma C, Ortega H. Effet du mepolizumab (MEPO) chez des patients atteints d’asthme sévère éosinophilique (ASE) précédemment traités par omalizumab (OMA). Rev Mal Respir 2016. [DOI: 10.1016/j.rmr.2015.10.636] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
48
|
Devine O, Harborne A, Lo WB, Weinberg D, Ciras M, Price R. Unusual placement of intrathecal baclofen pumps: report of two cases. Acta Neurochir (Wien) 2016; 158:167-70. [PMID: 26592253 PMCID: PMC4684582 DOI: 10.1007/s00701-015-2636-9] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2015] [Accepted: 11/02/2015] [Indexed: 11/30/2022]
Abstract
Intrathecal baclofen delivery via implantable pump represents an important modality for symptomatic relief in patients with chronic spasticity. Pumps are routinely implanted subcutaneously in the anterior abdominal wall. We describe two unusual cases where skin-related complications necessitated revision surgery in order to relocate the pump to alternative sites. The first patient was an international power canoeist, whose strenuous exercise programme interfered with his pump’s original siting. The second patient was a cachectic university student with a history of cerebral palsy, who maintained low body mass despite attempted weight gain. The relocation of these two intrathecal devices to the medial compartment of the right thigh and right iliac fossa, respectively, is described.
Collapse
Affiliation(s)
- Oliver Devine
- The Medical School, University College London, Gower Street, London, WC1E 6BT, UK.
| | - Andrew Harborne
- Hull Royal Infirmary, Anlaby Rd, Kingston upon Hull, HU3 2JZ, UK.
| | - William B Lo
- Department of Neurosurgery, Queen Elizabeth Medical Centre, Birmingham, B15 2TH, UK.
| | - Daniel Weinberg
- Salford Royal NHS Foundation Trust, Stott Lane, Salford, M6 8HD, UK.
| | - Mahesh Ciras
- Department of Rehabilitation and Musculoskeletal Medicine, University Hospital of North Staffordshire, Newcastle Road, Stoke-on-Trent, ST4 6QG, UK.
| | - Rupert Price
- Department of Neurosurgery, University Hospital of North Staffordshire, Newcastle Road, Stoke-on-Trent, ST4 6QG, UK.
| |
Collapse
|
49
|
Prazma C, Magnan A, Price R, Ortega H, Yancey S, Albers F. Effet du Mépolizumab® (MEPO) chez des patients atteints d’asthme sévère éosinophilique (ASE), corticodépendants et précédemment traités par omalizumab (OMA). Rev Mal Respir 2016. [DOI: 10.1016/j.rmr.2015.10.069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
50
|
|